OnKure (OKUR) CSO Hartley Dylan Receives Award; Options Repriced
$OKUR · OnKure Therapeutics, Inc.Research Summary
AI-generated summary of this SEC filing
OnKure (OKUR) CSO Hartley Dylan Receives Award; Options Repriced
What Happened
Hartley Dylan, Chief Scientific Officer of OnKure Therapeutics (OKUR), received a 50,000-share award (reported at $0.00) and was affected by a company-wide option repricing that involved 137,603 option shares on August 7, 2026. The repricing amended the exercise price of the affected options to $4.14 per share (the closing price that day). No cash proceeds were reported — this was an award and an amendment of existing option terms, not a cash purchase or open-market sale.
Key Details
- Transaction date: August 7, 2026; Form 4 filed August 11, 2026. (Filing appears to exceed the typical 2-business-day Form 4 deadline.)
- Award: 50,000 shares reported acquired at $0.00 (derivative award/grant).
- Repriced options: 137,603 option shares reported as cancelled/regranted (disposition to issuer and acquisition of derivative), exercise price amended to $4.14/share.
- Vesting notes: the 50,000 award vests 1/48th monthly starting September 7, 2026; the repriced options previously had 1/4 vested on June 9, 2025 with 1/48th vesting monthly thereafter (per footnotes).
- Repricing terms: applies to options with original exercise prices ≥ $10.00 for continuing employees; no change to vesting schedules, expiration dates, or share counts. A “Retention Period” runs from Aug 7, 2026 until Feb 7, 2028 (or a change in control); exercising repriced options before that end requires paying a premium equal to the original exercise price.
- Shares owned after transaction: not specified in the filing.
Context and investor takeaways
This filing documents a grant and a contractual amendment to existing options (an option repricing) rather than an open-market buy or sale. Repricing lowers the exercise price to the market-close price on the effective date but does not by itself produce cash or indicate immediate selling. The repriced options remain subject to original vesting schedules and a retention window that can require paying a higher “premium” exercise price if exercised early.